Literature DB >> 23550771

The expression of hypoxia-inducible factor-1 in primary brain tumors.

Joanna Reszec1, Robert Rutkowski, Lech Chyczewski.   

Abstract

PURPOSE: Primary brain tumors are common type of neoplasms. The most common are astrocytic tumors, so do meningiomas of various grades. The etiology is still unknown; however, there are lots of data presenting new theories about genetic alterations responsible for low- or high-grade astrocytic tumors development as well as meningiomas, despite this the results are divergent. The aim of the study was to evaluate hypoxia-inducible factor-1 (HIF-1) expression in meningiomas and astrocytic tumors of various grades.
MATERIAL AND METHODS: One hundred six cases of astrocytic tumors were divided into diffused astrocytoma (24 cases), anaplastic astrocytoma (40 cases) and glioblastoma groups (42 cases). Among glioblastoma group, 30 cases were secondary glioblastoma. One hundred fifty-four meningioma cases were divided as low-grade meningioma (G1: 104 cases) and high-grade meningioma groups (G2: 43 cases and G3: 7 cases). Twelve low-grade meningiomas transformed into high-grade tumors, 17 low-grade meningiomas recur within 12 years. HIF-1 expression was estimated using immunohistochemistry under the light microscope. Statistical analysis was performed in all examined groups.
RESULTS: HIF-1 expression was observed in 37.5% cases of diffused astrocytomas, in anaplastic astrocytomas 27.5% tumors were HIF-1 positive, in the glioblastoma goup HIF-1 expression was observed in 83.3% cases. All secondary glioblastomas were positive for HIF-1. Low-grade meningiomas were positive for HIF-1 in 55.7%, in high-grade meningiomas, HIF-1 expression was observed in 84%. All meningiomas, which progressed from low- to high-grade meningiomas, were HIF-1 positive.
CONCLUSION: HIF-1 expression is associated with the development and progression of both astrocytic tumors and meningiomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23550771     DOI: 10.3109/00207454.2013.789874

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  5 in total

1.  Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.

Authors:  Amber J Giles; Shuyu Hao; Michelle Padget; Hua Song; Wei Zhang; John Lynes; Victoria Sanchez; Yang Liu; Jinkyu Jung; Xiaoyu Cao; Rika Fujii; Randy Jensen; David Gillespie; Jeffrey Schlom; Mark R Gilbert; Edjah K Nduom; Chunzhang Yang; John H Lee; Patrick Soon-Shiong; James W Hodge; Deric M Park
Journal:  JCI Insight       Date:  2019-10-17

2.  [Primary culture of human malignant meningioma cells and its intracranial orthotopic transplantation in nude mice].

Authors:  Mei-Xin Hu; Jia-le Liu; Xuan-Bo Chen; An-Qi Xu; Song-Ren Shu; Chao-Hu Wang; Yi Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-03-20

3.  AMP kinase promotes glioblastoma bioenergetics and tumour growth.

Authors:  Rishi Raj Chhipa; Qiang Fan; Jane Anderson; Ranjithmenon Muraleedharan; Yan Huang; Georgianne Ciraolo; Xiaoting Chen; Ronald Waclaw; Lionel M Chow; Zaza Khuchua; Matthew Kofron; Matthew T Weirauch; Ady Kendler; Christopher McPherson; Nancy Ratner; Ichiro Nakano; Nupur Dasgupta; Kakajan Komurov; Biplab Dasgupta
Journal:  Nat Cell Biol       Date:  2018-06-18       Impact factor: 28.824

Review 4.  Hypoxia: The Cornerstone of Glioblastoma.

Authors:  Marta Domènech; Ainhoa Hernández; Andrea Plaja; Eva Martínez-Balibrea; Carmen Balañà
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

Review 5.  Stress Response Leading to Resistance in Glioblastoma-The Need for Innovative Radiotherapy (iRT) Concepts.

Authors:  Stephanie E Combs; Thomas E Schmid; Peter Vaupel; Gabriele Multhoff
Journal:  Cancers (Basel)       Date:  2016-01-13       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.